Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as honeybee venom (Apitoxin (Korea) Apitox (USA))
honeybee venom · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| honeybee venom (Apitoxin (Korea) Apitox (USA)) | DRUG | multiple intradermal injections of 100 ug pure honeybee venom |
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
Honeybee venom is being developed as an injectable treatment for osteoarthritis of the knee, aimed at reducing joint pain and inflammation. It is a small molecule therapeutic candidate studied in a Phase 2 trial in the United States. It is not an approved therapy and remains investigational.
Honeybee venom is being developed by Apimeds Pharmaceuticals US, Inc., which trades under the ticker APUS. The company is advancing the candidate for musculoskeletal indications, specifically osteoarthritis of the knee, through clinical development.
Honeybee venom is in Phase 2 clinical development. One Phase 2 trial has been completed, and no trials are currently active. The candidate is investigational and has not been approved by the FDA for any indication.
Honeybee venom has been studied in one completed Phase 2 trial, NCT00949754, titled Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation. The trial enrolled 40 participants with osteoarthritis of the knee in the United States, included both sexes, and required participants to be at least 35 years old.
Yes. Honeybee venom is also known as Apitoxin in Korea and Apitox in the United States. These names refer to the same product candidate being developed by Apimeds Pharmaceuticals US, Inc. for osteoarthritis of the knee.
The Phase 2 trial NCT00949754 was a randomized, double-blind study of 40 participants with osteoarthritis of the knee. It was conducted in the United States and is listed as completed. The trial used an uncontrolled design, meaning participants were not compared against a placebo or active comparator group.